These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 11815500)

  • 21. The ORLIstat and CArdiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORLICARDIA) Study.
    Didangelos TP; Thanopoulou AK; Bousboulas SH; Sambanis CL; Athyros VG; Spanou EA; Dimitriou KC; Pappas SI; Karamanos BG; Karamitsos DT
    Curr Med Res Opin; 2004 Sep; 20(9):1393-401. PubMed ID: 15383188
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Spotlight on orlistat in the management of patients with obesity.
    Curran MP; Scott LJ
    Treat Endocrinol; 2005; 4(2):127-9. PubMed ID: 15783249
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the effects of sibutramine and orlistat on obese, poorly-controlled type 2 diabetic patients.
    Chou KM; Huang BY; Fanchiang JK; Chen CH
    Chang Gung Med J; 2007; 30(6):538-46. PubMed ID: 18350737
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term pharmacotherapy for obesity and overweight.
    Padwal R; Li SK; Lau DC
    Cochrane Database Syst Rev; 2003; (4):CD004094. PubMed ID: 14584004
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes.
    Derosa G; Cicero AF; D'Angelo A; Fogari E; Maffioli P
    J Clin Pharm Ther; 2012 Apr; 37(2):187-95. PubMed ID: 21812797
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
    Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
    Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Comment of J. Fritze: Is therapy of obesity with orlistat medically necessary?].
    Wirth A
    Versicherungsmedizin; 1999 Sep; 51(3):137-8; author reply 138-9. PubMed ID: 10516837
    [No Abstract]   [Full Text] [Related]  

  • 28. Cost-effectiveness of weight-management pharmacotherapies in Canada: a societal perspective.
    Olivieri AV; Muratov S; Larsen S; Luckevich M; Chan K; Lamotte M; Lau DCW
    Int J Obes (Lond); 2024 May; 48(5):683-693. PubMed ID: 38291203
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized double-blind study comparing the efficacy and safety of orlistat versus placebo in obese patients with mild to moderate hypercholesterolemia.
    de Castro JJ; Dias T; Chambel P; Carvalheiro M; Correia LG; Guerreiro L; Marques O; Medina JL; Nobre E; Nunes JS; Pereiraa MC; Polónia J; Portugal J; Raimundo A; Ruas A; da Silva PM; Vasconcelos C; Reis JL; Teles AG
    Rev Port Cardiol; 2009 Dec; 28(12):1361-74. PubMed ID: 20301983
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A systematic review of the clinical effectiveness of orlistat used for the management of obesity.
    O'Meara S; Riemsma R; Shirran L; Mather L; ter Riet G
    Obes Rev; 2004 Feb; 5(1):51-68. PubMed ID: 14969507
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of orlistat in patients with diabetes: improvement in glycaemic control and weight loss.
    Rowe R; Cowx M; Poole C; McEwan P; Morgan C; Walker M
    Curr Med Res Opin; 2005 Nov; 21(11):1885-90. PubMed ID: 16307710
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Orlistat: a review of its use in the management of obesity.
    Hvizdos KM; Markham A
    Drugs; 1999 Oct; 58(4):743-60. PubMed ID: 10551441
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of orlistat on cardiovascular disease risk in obese adults.
    Swinburn BA; Carey D; Hills AP; Hooper M; Marks S; Proietto J; Strauss BJ; Sullivan D; Welborn TA; Caterson ID
    Diabetes Obes Metab; 2005 May; 7(3):254-62. PubMed ID: 15811142
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Orlistat in the treatment of Type 2 diabetes mellitus.
    Kelley DE; Jneidi M
    Expert Opin Pharmacother; 2002 May; 3(5):599-605. PubMed ID: 11996637
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of orlistat treatment and placebo in obese type 2 diabetic patients.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; D'Angelo A; Fogari E; Palumbo I; Randazzo S; Cicero AF
    Expert Opin Pharmacother; 2010 Aug; 11(12):1971-82. PubMed ID: 20569086
    [TBL] [Abstract][Full Text] [Related]  

  • 36. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.
    Toplak H; Ziegler O; Keller U; Hamann A; Godin C; Wittert G; Zanella MT; Zúñiga-Guajardo S; Van Gaal L
    Diabetes Obes Metab; 2005 Nov; 7(6):699-708. PubMed ID: 16219013
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Orlistat: a review of its use in the management of obesity.
    Henness S; Perry CM
    Drugs; 2006; 66(12):1625-56. PubMed ID: 16956313
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Orlistat.
    Wong NN; Cheng-Lai A
    Heart Dis; 2000; 2(2):174-81. PubMed ID: 11728255
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New aspects in the management of obesity: operation and the impact of lipase inhibitors.
    Uusitupa M
    Curr Opin Lipidol; 1999 Feb; 10(1):3-7. PubMed ID: 10095983
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study.
    Richelsen B; Tonstad S; Rössner S; Toubro S; Niskanen L; Madsbad S; Mustajoki P; Rissanen A
    Diabetes Care; 2007 Jan; 30(1):27-32. PubMed ID: 17192328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.